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Abstract
Background: When a randomised trial is subject to deviations from randomised treatment, analysis according to
intention-to-treat does not estimate two important quantities: relative treatment efficacy and effectiveness in a
setting different from that in the trial. Even in trials of a predominantly pragmatic nature, there may be numerous
reasons to consider the extent, and impact on analysis, of such deviations from protocol. Simple methods such as
per-protocol or as-treated analyses, which exclude or censor patients on the basis of their adherence, usually
introduce selection and confounding biases. However, there exist appropriate causal estimation methods which
seek to overcome these inherent biases, but these methods remain relatively unfamiliar and are rarely implemented
in trials.
Methods: This paper demonstrates when it may be of interest to look beyond intention-to-treat analysis for answers
to alternative causal research questions through illustrative case studies. We seek to guide trialists on how to handle
treatment changes in the design, conduct and planning the analysis of a trial; these changes may be planned or
unplanned, and may or may not be permitted in the protocol. We highlight issues that must be considered at the trial
planning stage relating to: the definition of nonadherence and the causal research question of interest, trial design,
data collection, monitoring, statistical analysis and sample size.
Results and conclusions: During trial planning, trialists should define their causal research questions of interest,
anticipate the likely extent of treatment changes and use these to inform trial design, including the extent of data
collection and data monitoring. A series of concise recommendations is presented to guide trialists when considering
undertaking causal analyses.
Keywords: Nonadherence, Non-compliance, Deviation from randomised treatment, Trial analysis, Causal effect
modelling
Background
How and why treatment changes occur
Nonadherence with prescribed intervention is a com-
mon problem affecting all areas of general medical
practice [1, 2]. The wide reaching clinical and eco-
nomic consequences of nonadherence have prompted
extensive research into its causes, extent and impact
spanning more than four decades [3]. However, despite
these efforts, the prevalence of nonadherence to long-
term treatment has remained stable. In a randomised trial,
this problem translates into deviation from original rando-
mised treatment, which may be built into, or may contra-
vene, the treatment protocol, depending on the trial’s
focus and degree of pragmatism.
Treatment changes are common in trials: a recent
review found that 98 of a cohort of 100 trials pub-
lished in four high-quality general medical journals
reported some form of deviation from randomised
intervention. However, the analysis methods used to
adjust for these changes from randomised treatment
were often inadequate [4]. Any deviation from rando-
mised treatment presents a challenge when analysing
data. In particular, such deviations impact on the
interpretation of trial analyses because the underlying
* Correspondence: s.r.dodd@liv.ac.uk
1Department of Biostatistics, Institute of Translational Medicine, University of
Liverpool, Liverpool L69 3GS, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dodd et al. Trials  (2017) 18:498 
DOI 10.1186/s13063-017-2240-9
assignment mechanism (randomisation), which forms
the basis for unbiased hypothesis testing, no longer
reflects the actual treatment received. If all treatment
deviations are ignored and analysis is carried out
according to randomisation (as in intention-to-treat
(ITT) analysis), inference can be made only on the
effectiveness of the treatment policy or prescription in
the trial conditions, rather than on the biological effi-
cacy (or causal effect) of treatment actually received.
Inherent interest in causal effects
Although ITT is generally recognised as the most appro-
priate approach for primary analyses of pragmatic
clinical trials, mirroring the randomised allocation and
thus preventing selection bias, there nevertheless may be
interest in estimating efficacy of treatment, or the effect-
iveness of treatment in an alternative setting to that
provided in the trial. The trial may, for practical or eth-
ical reasons, require a certain treatment protocol to be
followed; however, the research question of interest may
carry an alternative focus to that directly implied by the
treatment protocol. For example, crossover to the alter-
native trial treatment (or non-trial treatments) may be
necessary for medical reasons; however, the research
question of greatest interest may relate to the effective-
ness of treatment in the absence of such treatment
switches.
The research question of greatest interest may differ
between stakeholders. For example, a motivated patient
interested in the likely benefit of treatment if they comply
with their prescription may be interested in the causal
effect of treatment taken as prescribed while allowing for
necessary changes if they experience side effects or treat-
ment inefficacy. Alternatively a policy-maker may be inter-
ested in applying trial results to a general community
setting where treatment changes occur to differing degrees
from those observed in the trial [5]. Differently again,
funding decisions by regulatory bodies, such as The
National Institute for Health and Clinical Excellence
(NICE), often require full cost-effectiveness analysis which
typically relate to the effect of treatment taken for life
(particularly for drugs which impact on survival). As such,
they require estimation of causal effects which factor out
all changes from originally randomised treatment that do
not reflect typical real-life availability of treatments [6].
Bias from per-protocol and as-treated analyses
Analysts must be mindful of the potential for bias when
analysing according to anything other than randomised
allocations, in particular the effect on both internal and
external validity of a trial.
Excluding or censoring patients who deviate from
randomised treatment protocol (as in ‘per protocol’
(PP) analyses) affects the generalisability (external
validity) of a trial, as those who persevere with treat-
ment protocol represent a non-random sample of the
original group of trial participants. More seriously, PP
analysis is likely to introduce selection bias and thus
also affect the internal validity of a trial. This is
because the various treatment protocols being com-
pared present different challenges to adherence, mak-
ing the compliant subgroups of each randomised
group unlikely to be comparable [7]. Given that those
intermediate confounding factors which influence a
patient’s compliance status as well as their prognosis
(and hence outcome) typically remain unmeasured
(and may even be unmeasurable), it is often impos-
sible to compare the profiles of these factors between
groups. The results of PP analysis are, therefore, likely
to be unreliable because of these hidden confounding
or selection effects [8].
A variation on PP analysis is analysis according to
treatment received (‘as-treated’). Rather than exclud-
ing or censoring patients, as-treated (AT) analyses
compare patients according to the (predominant)
treatment received, but are, therefore, never likely to
be valid as randomisation is disregarded entirely [9].
Despite the likelihood of selection bias, these simple
methods are frequently used to estimate treatment
effects beyond that of ITT; furthermore, analyses
purporting to be ‘ITT’ often in fact exclude patients on
the basis of treatment adherence, therefore, failing to
meet ITT analysis principles [4].
More appropriate causal methods exist but are rarely
used
There exist more appropriate causal estimation
methods which seek to overcome the inherent selec-
tion and confounding biases of simple methods [10],
but these methods remain relatively unfamiliar and
are rarely implemented in trials [4]. This may be due
to a lack of awareness of how to practically apply the
methods, as well as their potential complexity. When
planning to implement such methods, it is necessary
to consider how the potential treatment deviations
will impact on the conclusions drawn from the trial
analyses, in relation to the causal research question of
interest. Thus, in this paper, we seek to describe a
range of trial scenarios where it may be appropriate
to look beyond ITT, and to consider the causal
research question of interest relative to the treatment
deviations observed in the trial. We also discuss
issues that must be considered as part of the causal
estimation process, in terms of modelling and inter-
pretation of results, and highlight the necessary plan-
ning of data collection and statistical analysis
methods to ensure transparency and applicability of
chosen statistical methods.
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Aim
The aim of this paper is to provide a framework for the
design, conduct and interpretation of randomised
controlled trials subject to treatment changes, highlighting
issues that must be considered at the trial planning stage
regarding data collection and analysis beyond ITT. In a
complementary paper [11], we demonstrate the applica-
tion of appropriate causal methods in the analysis of a trial
featuring typical treatment complications associated with
chronic disease and longitudinal treatment and follow-up
periods.
Framework and recommendations
Anticipate the possible nature and extent of treatment
changes
The first step when planning to carry out causal analysis
is to consider how deviations from treatment assignment
are likely to manifest themselves, both within the trial
setting and the particular (potentially hypothetical)
setting to which the trial results are to be applied.
Participant compliance may be all-or-nothing or par-
tial, fluctuating in a time-dependent manner. Treatment
switches may take place in one treatment arm only (for
example, when control patients are given the option to
switch to the experimental treatment on disease progres-
sion) or may be very complex (for example, when all
patients are permitted to switch to the alternative trial
treatment or external non-trial treatments).
In a trial setting, ‘adherence’ comprises more than
the patient simply following a prescribed treatment
regimen or therapeutic intervention; it also includes
cooperation on the part of treatment providers in
following the procedures as specified in the treatment
protocol. Treatment protocol deviations may also be
manifested as (or masked by) absence of outcome
data, which is generally caused by withdrawal of
patient consent, loss to follow-up (LTFU) or missing
assessments. Patient withdrawal from treatment often
coincides with premature withdrawal from the trial,
as outcome data are often collected at the time of
treatment delivery (for example, when patients receive
treatment and provide follow-up information at the
same clinic visit). Patients may become unavailable
for follow-up or withdraw their consent to taking part
in the trial for reasons related or unrelated to their
condition or treatment.
Defining causal research question of interest
Once the nature and extent of the likely treatment
changes have been identified, it is necessary to define
the causal research question of interest, which will in
turn allow identification of the causal estimand of
interest (that is, the quantity to be estimated). When
interest lies in estimating any estimand beyond the
effect of treatment assignment, it is important to con-
sider how the treatment patterns in the trial setting
relate to this causal estimand. In particular, it is
necessary to differentiate those treatment deviations
which would be usefully factored out of analysis (be-
cause they contravene the treatment path of interest)
from those which are inherently part of the treatment
course (such that their occurrence is not informative
from a causal perspective) [12].
In order to illustrate how treatment changes mani-
fested within a trial scenario may relate to a particu-
lar causal research question, we present four varying
causal scenarios illustrated using six real-life trials as
case studies (see Table 1).
Interest in efficacy despite inherently pragmatic trial
design
It may be necessary for a trial to be designed with in-
herently pragmatic characteristics (such as permitting
patients to switch from their original randomised
treatment if it is found to be inefficacious or un-
acceptable) in order to mirror usual clinical practice
and increase acceptability to participants. However,
despite a necessarily pragmatic design, it may be of
interest to estimate the underlying efficacy of treat-
ment if taken as originally randomised. In such a
case, causal analyses would aim to factor out treat-
ment changes which did not reflect the original
intended treatment protocol.
This scenario is particularly likely in the case of trials for
chronic conditions, where treatment changes may be com-
mon due to problems related to side effects or inefficacy of
treatment; two such clinical trial case studies are presented
in illustration.
MRC hypertension trial
The three-arm Medical Research Council (MRC) hyper-
tension trial [13] compared the long-term efficacy of two
antihypertensive drugs (diuretic or beta-blocker) with
placebo in prevention of cardiovascular (CV) events and
mortality in older patients. The trial protocol permitted
changes to randomised treatment, reflecting what would
typically occur in clinical practice. If the randomised
treatment failed to control blood pressure, an additional
drug (initially the other active trial drug) would be
prescribed. If a patient experienced unacceptable side ef-
fects on randomised treatment, an alternative treatment
(commonly the other active trial drug) would instead be
prescribed.
The ITT analysis of the MRC hypertension trial appro-
priately addressed the primary question of interest, namely
whether there was any difference in the effectiveness of
the treatment policies of starting treatment with one
randomised intervention, followed by any treatment
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changes that became necessary. The effectiveness of the
active treatments in preventing CV events compared to
placebo was apparent from the ITT analysis; however,
when the two active treatment groups were compared dir-
ectly in an ITT analysis, it was unexpectedly found that
the rate of CV events was significantly lower in the diur-
etic group compared with the beta-blocker group.
Patients randomised to receive a beta-blocker were
more often prescribed supplementary drugs than those
randomised to diuretic treatment, and they experienced
significantly more withdrawals than the diuretic group. In
light of the frequency of these treatment changes, the trial
investigators explored whether, and how much of, the un-
expected ITT difference between the active treatment
groups was in fact due to differential rates of treatment
changes that occurred in the different randomised groups.
White et al. adjusted for changes in prescribed treatment
in this trial using both simple [14] and randomisation-
based [15] methods (introduced in a complementary
paper [11]).
SANAD trial
The Standard And New Antiepileptic Drugs (SANAD)
trial [16, 17], an unblinded randomised comparison of
a number of standard and new antiepileptic drugs
(AEDs), is another example of a drug trial in chronic
disease which featured changes to treatment prescrip-
tion, but this trial design was further complicated by
the need to balance efficacy and safety. Existing first-
line treatments with previously proven efficacy often
lead to unacceptable side effects; thus, if a new drug
could be shown to be superior in terms of tolerability,
it was deemed necessary only to demonstrate its non-
inferiority in terms of seizure control (assessed in
terms of time to 12-month remission, T12mR, defined
as the time from randomisation to reaching a 12-
month period free of seizures). The need to employ
methods to determine non-inferiority (or equivalence)
is complicated when treatment deviations occur, as
deviations typically result in merging of treatment
experiences across treatment arms, leading to treat-
ment effects that are more similar than would have
otherwise been observed between randomised groups.
As such, ITT analysis is anticonservative when under-
taking such analyses, necessitating estimation methods
beyond ITT and PP, as both of these methods are
likely to be biased in this setting.
Changes to prescribed treatment are common in
epilepsy, primarily due to treatment inefficacy (indicated
by inadequate seizure control, ISC) or intolerability (due
to unacceptable adverse events, UAEs). Thus, the treat-
ment protocol in SANAD was chosen to be entirely
pragmatic, permitting changes from randomised treat-
ment that reflected everyday clinical care. Patients expe-
rienced a variety of treatment changes during trial
follow-up, including changes to prescribed treatment
Table 1 Case studies illustrating scenarios requiring causal estimation
Causal estimation
scenario
Case study Treatment changes adjusted for Causal question being addressed
Interest in efficacy despite pragmatic trial design
MRC hypertension
trial
Addition of alternative treatments due to inadequate blood
pressure control, or switches to alternative treatments due
to side effects
Treatment efficacy in absence of treatment
switches or additions
SANAD trial Withdrawal from randomised treatment, addition of alternative
treatments, or switches to alternative treatments due to
inadequate seizure control
Treatment efficacy in absence of treatment
changes due to inadequate seizure control
Trial protocol differs from practice
Vitamin A trial Non-receipt of trial drug due to failure of the drug distribution
system
Treatment efficacy among those who would
have complied with active treatment if
randomised to receive it
Contamination (control arm receives intervention)
Honey trial More extreme forms of treatment, such as antibiotics, surgery
or radiotherapy
Patient or clinician decision to switch from conventional
dressings to honey
Treatment efficacy in absence of any
treatment changes
PACIFICO trial Switches from standard to new treatment on disease
progression
Treatment efficacy in absence of treatment
switches from standard to new treatment on
progression
Interest in efficacy if taken as prescribed
Coronary Drug
Project
Failure to take treatment according to prescribed schedule Treatment efficacy among those who
complied with treatment protocol
MRC Medical Research Council, PACIFICO Purine-Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients, SANAD Standard and
New Antiepileptic Drugs
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dose, complete withdrawal from randomised treatment,
addition of other trial (or non-trial) treatments to aid
seizure control, switching to another trial (or non-trial)
treatment or continued prescription of another treat-
ment still being taken at randomisation.
When treatment changes occur prior to achieving
remission, the assessment of each randomised AED
according to ITT is a distorted assessment of the true ef-
ficacy, as it is unclear which AED should be attributed
with success or failure in achieving remission. Although
it is acknowledged that treatment changes prior to
T12mR due to UAEs are inevitable and necessary, expert
clinicians argue that changes due to ISC may in fact be
avoided by more appropriate dosing of randomised drug.
It was, therefore, of particular interest in this trial to
supplement ITT analysis with a causal analysis adjusting
only for treatment changes occurring due to ISC. The
causal question of interest in this trial is: what is the
relative benefit of each drug in achieving a minimum
T12mR, in the absence of any changes to prescribed
treatment due to ISC?
Potential analyses investigating this causal research
question are explored in more detail in the complemen-
tary paper [11]. Data were available on the nature and
timing of changes to prescribed treatment, as well as
time-varying covariates that impact on both treatment
change and remission, namely seizure counts, adverse
events and treatment dose (as the competing reasons for
treatment change, ISC and UAE, are inversely related via
treatment dose: as dose increases, seizure control is
likely to improve but adverse effects may well increase).
These data facilitated the use of two different models:
the structural failure time model (SFTM, a model based
on the potential outcomes framework and the assumed
balance between randomised arms in terms of their
underlying, potentially unobserved, outcome with the
control treatment) and the inverse probability of censor-
ing weighting (IPCW) method (whereby bias introduced
with artificial censoring of patients at the point of their
first treatment change is addressed by adjusting for all
factors that jointly predict treatment change and outcome,
under the assumption of no unmeasured confounders).
Trial protocol differs from what will be used in practice
Another scenario which may necessitate causal ana-
lysis is when the treatment protocol implemented in
the trial differs from how treatment will be delivered
in practice.
Vitamin A trial
A cluster randomised trial assessed the effect of treat-
ment with vitamin A (versus no treatment) on infant
mortality rates in 450 villages in rural Indonesia [18].
Non-receipt of the trial drug occurred as a direct
result of the failure of the trial drug distribution
system to reach a substantial proportion of those
randomised to receive treatment, rather than due to
nonadherence on the part of participants; as such,
20% of the children randomised to receive vitamin A
failed to do so.
Investigators were particularly interested in causal
analysis beyond ITT because, if proved to be efficacious,
the treatment distribution method used in practice to
provide vitamin A supplementation to the Indonesian
population (fortification of a common daily food) would
differ from that used in the trial (oral treatment). Thus,
it was considered of greater interest to estimate the
biological efficacy of vitamin A supplementation, which
could then be interpreted in the light of a likely rate of
successful delivery of the chosen vitamin A fortification
method, providing an estimate of the effectiveness of the
programme to be used in practice, rather than simply
the effectiveness of the trial distribution programme
(estimated using ITT).
For this trial, Sommer and Zeger [7] proposed a compari-
son of outcomes among those who would have complied
with active treatment if randomised to receive it, later
referred to as the complier average causal effect (CACE)
estimate. The CACE estimate for the relative risk of infant
mortality suggested that vitamin A supplementation would
provide more than 70% reduction in infant mortality rates,
compared to the ITT relative risk which suggested approxi-
mately 40% reduction in risk with orally administered vita-
min as distributed in the trial.
Contamination (whereby control arm receives
intervention)
When investigators are interested in comparing the effect
of an experimental treatment against a control intervention,
the problem of contamination (when participants rando-
mised to control receive the experimental intervention)
causes dilution in the estimate of the true efficacy of experi-
mental treatment, as the treatment experience of the two
groups becomes more similar than originally intended. In
this case, it is of interest to compare the randomised groups
factoring out the impact of contamination in the control
group. This is a common scenario of interest for health
economic evaluations for licensing purposes, as such
assessments seek to estimate the cost-effectiveness of treat-
ment compared to the alternative control scenario reflect-
ing a complete lack of availability of the experimental
treatment.
Contamination of the control group with the experimen-
tal treatment is not uncommon; control participants are
made aware of the potential efficacy of the experimental
treatment when given information about the trial, and thus
it is not surprising that they may seek to obtain the experi-
mental treatment. Furthermore, the trial treatment protocol
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may permit or encourage treatment switches (for example,
on disease progression). Two case studies are presented
here, featuring different reasons for contamination in vari-
ous disease areas.
Honey trial
This trial compared the effect of topical medical-grade
honey with conventional dressings on wound-healing
rates [19]. Despite the trial’s relatively straightforward
treatment protocol, a number of deviations from treat-
ment protocol occurred in follow-up.
In cases of deterioration of the wound, it was ethically
necessary to allow patients to cease randomised treat-
ment in order to receive more extreme forms of treat-
ment, such as antibiotics, surgery or radiotherapy.
Expectation about honey treatment also led to treat-
ment switches from the randomised conventional arm to
honey. Honey was not available on NHS prescription at
the time, which (coupled with considerable publicity re-
garding its efficacy) created a recruitment incentive for
both patients and clinical staff. However, the anticipated
efficacy of honey, along with the unblinded nature of the
trial, frequently led to disappointment and premature
dropout when patients were not allocated to receive it.
Treatment switches also occurred because of decisions
made by clinical staff external to the trial who were keen
for their patients to receive honey, especially their youn-
ger, fitter patients expected to make good progress with
honey treatment. In contrast, some patients believed that
honey treatment was causing additional pain to their
wound, which led to a request to switch to conventional
treatment.
Although it was necessary to allow patients to receive
alternative or more powerful treatment if they experi-
enced side effects or wound deterioration, the primary
trial objective was to ascertain the biological efficacy of
honey treatment when compared to best standard care.
As such, the estimand of interest was the causal effect of
honey treatment compared with conventional dressings,
factoring out any treatment changes from randomised
treatment.
PACIFICO trial
Purine-Alkylator Combination In Follicular lymphoma
Immuno-Chemotherapy for Older patients (PACIFICO)
is a randomised trial (currently recruiting patients)
comparing two forms of chemotherapy for patients with
follicular lymphoma, assessing which treatment is
optimal in terms of efficacy in controlling the spread of
the disease balanced against toxicity.
The treatment protocol specifies that cycles of inpatient
chemotherapy be delayed or ceased if patients experience
excessive toxicity. However, any such deviations from the
ideal course of treatment are accepted as an integral part
of the variation of treatment according to a patient’s needs
and symptoms. In contrast, the treatment changes of
interest in terms of causal impact are those made at the
point of disease progression. When treating patients for a
cancer that may later progress or relapse, it is often an
ethical requirement to permit switching to alternative
treatments when their disease worsens.
The primary outcome in trials where such treat-
ment changes are expected is usually progression-free
survival (PFS) or relapse-free survival (RFS), defined
as the time from randomisation to progression (or
relapse) or death, whichever occurs first. Such an out-
come is not affected by switches at progression (or
relapse), as they occur after the event of interest and
thus have no causal impact. The traditionally more
common outcome of overall survival (OS) is, however,
confounded by such treatment changes, as merging of
the treatment experience in the two arms following
progression or relapse causes diminished OS treat-
ment effects. However, OS is objective and is usually
the most important outcome for the patient, as well
as being of primary interest for health economics and
policy decisions. Thus, on trial completion, it will be
of interest to estimate treatment efficacy in terms of
OS for this trial using SFTM or IPCW, avoiding con-
founding due to treatment switches on progression.
Inform patients and clinicians of efficacy if taken as
prescribed
Finally, if trial participants experience problems following
the treatment protocol of a treatment which is neverthe-
less believed or proven to be efficacious, it may be of
interest to estimate a causal treatment estimate which fac-
tors out the effect of participant nonadherence in order to
demonstrate to clinicians and patients the potential opti-
mal efficacy if the treatment prescription is followed as
prescribed.
Coronary Drug Project
The Coronary Drug Project (CDP) assessed the long-
term efficacy and safety of a number of drugs, including
clofibrate, against placebo in preventing coronary heart
disease (CHD) [20]. Nonadherence to treatment proto-
col in the CDP occurred as a result of patients failing to
take the correct dose of their randomised treatment.
Adherence data suggested that one third of the patients
(33.5% of the clofibrate group and 32.7% of the placebo
group) took less than 80% of their prescribed medication.
Overall clofibrate did not appear to affect mortality
when compared to placebo: 5-year mortality in the
clofibrate group was 20.0% compared to 20.9% in the
placebo group. However, given the high prevalence of
non-compliance, the study investigators and external
parties became interested in whether the ITT result may
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have masked a true effect of treatment among those
who received clofibrate as intended. Analysis using
causal methods, such as CACE estimation to assess the
potential effect of treatment among those who ‘complied’
with treatment, would equally be informative for
patients wanting to know the benefit of adhering to the
relatively complicated treatment schedule.
Trial designs to address deviation from randomised
treatment
As evident in this exposition of trials, deviation from
randomised treatment is not always due to a lack of
cooperation on the part of the patient or a flaw in the de-
sign or methodology of a trial [21]; indeed, nonadherence
issues may be inherent to the disease and treatment
process. If foreseen, these may be incorporated into the
design of a trial during the planning stage. For example,
encouragement designs may be employed (whereby en-
couragement to take the treatment is randomised, rather
than the treatment itself ) if the consent process is likely to
lead to adherence problems. This may be useful if patients
are unlikely to accept the idea of randomisation in the
given setting or if informing patients about treatment may
affect the adherence of patients who end up in the control
arm [22].
Other simple design features may be incorporated to aid
adherence analyses; for example, compliance measure-
ments may be taken during a baseline placebo run-in
phase to obtain information on baseline predictors of
compliance (which, when included in CACE and other
causal models, may help regain power by reducing out-
come variation [23]). Alternatively, it may be possible to
seek out patient preferences before they are randomised
in order to obtain information on preference effects for
better prediction of underlying compliance [24]. Likewise,
if a trial is likely to involve numerous forms of treatment
change (for example, if a variety of treatment options are
available on disease progression) or if extreme degrees of
nonadherence are expected (for example, when random-
isation is unlikely to be acceptable to most patients), it
may be helpful to pre-empt the problem by designing the
trial such that specific sequences of treatment are assigned
from randomisation, or repeat randomisations take place
as and when patients require different treatments. One
design of particular importance in chronic conditions
where an individual patient’s response may change over
time, is the sequential multiple assignment randomised
trial (SMART) for the estimation of dynamic treatment
regimens [25–27]. SMART designs are particularly appro-
priate for diseases where sequential phases of treatment
are common; for example, chronic conditions like asthma,
epilepsy and cancer (requiring different first- and second-
line treatments following diagnosis and progression, re-
spectively) and behavioural or psychological interventions.
They aim to better estimate the optimal treatment pack-
age (sequence of treatments) for individuals rather than
for diagnoses, thus seeking out personalised medicine tai-
lored to suit patients (for example, according to their gen-
etic profile or at a more macro level of characteristics,
such as side effect profiles) [28]. However, such designs
may themselves be subject to nonadherence (when clini-
cians prescribe alternatives to the randomised treatment
sequences) and may be overly complex or lengthy.
Appropriate data collection
Having identified which treatment changes impact on
the causal estimate of interest, it is necessary to ensure
that relevant data on treatment adherence are recorded
to facilitate this estimation. Appropriate measurement
techniques must be implemented in order to capture
information on the particular manifestations of nonad-
herence that are relevant to the clinical setting, in par-
ticular to the disease, treatment and patient population
being studied, and the research questions of interest.
The measures used to record participant compliance or
other treatment changes should be described in suffi-
cient detail to allow assessment of the reliability of the
measurements [29].
Adherence or treatment prescription information must
be recorded for both treatment arms. Similarly, it may
be necessary to supplement data on how well the
patients adhere to their original randomised prescription
with information on whether they sought alternative
treatments or contraindications.
Barriers to accurate collection of treatment adherence
data are many, and methods typically used in trials have
been discredited, as they are easy to falsify (pill counts),
rely on unrealistic or biased recall by patients (patient
interviews), or may be resisted by patients (treatment
diaries). Similarly, health care providers who (in their
opinion, justifiably) deviate from randomised treatment
regimens when prescribing or administering patients’
treatment may prefer not to disclose such treatment
protocol deviations.
Indeed, trialists may feel overwhelmed when faced
with the likelihood of numerous forms of deviation from
randomised treatment which typically occur with pre-
scription of long-term medication in trials and in clinical
practice. For example, treatment switches, additions,
withdrawals (permanent and/or intermittent) and incor-
rect treatment administration may occur, potentially in
both treatment arms and involving trial and non-trial
treatments. In such cases, rather than attempting to
collect (potentially unreliable) data on all sources of
nonadherence to randomised treatment, it will be
simpler to identify which features of nonadherence will
impact on the outcome, and then focus on how to ob-
tain accurate data on these features alone, which can
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meaningfully be used to inform relevant analysis tech-
niques. Furthermore, accurate data collection on treat-
ment adherence is often costly, thus adding to the
importance of focussed data collection. The complexity
and detail of available data will depend on the compli-
ance measurement method. When relying on patient
self-report (for example, pill counts, treatment diaries,
smartphone apps or direct questioning in clinic), it is
crucial that patients are made to feel at ease in reporting
their true adherence, rather than being concerned about
the consequences of disclosing suboptimal adherence;
they must, therefore, be reassured of their valuable
contribution when providing accurate adherence infor-
mation. More objective measures of adherence include
medication event monitoring systems (MEMS, which
record the exact time and date of opening or activation
of drug dispensers [30]), measurement of drug metabo-
lites or markers in bodily fluids and direct observation
of therapy (feasible only for monitoring single-dose or
intermittent treatment of hospitalised patients rather
than long-term self-administered treatment).
The need for relevant adherence data collection
highlights the importance of considering causal esti-
mation during the planning stage of a trial, rather
than simply at the point of statistical analysis. Given
that adherence is typically a multifaceted feature of
patient behaviour which is difficult to measure and
quantify, it is important to consider which data
should be collected and how, such that analysis ad-
justs for clinically relevant measures of treatment re-
ceived. The method used to collect compliance data
will determine the format of these data and how the
data may be included in the model; thus, it will be
necessary to consider how to collect this information
accurately (considering the potential for measurement
errors) and in an unbiased way. In particular, fore-
thought of the likely missingness mechanisms may
allow procedures to be employed in order to counter
such biases. Furthermore, the complexities associated
with recording compliance data mean that it may be
useful to pilot any data collection forms prior to trial
recruitment in order to ensure sufficient clarity for
treatment providers, assessors and patients.
Without the collection of required data, any neces-
sary statistical methods will never be realised; thus, it
is important to plan which variables should be
collected, relevant to the chosen statistical methods,
with consideration of how these compliance and
covariate measures will be measured in practice.
Statistical analysis may require information, not only
on the relevant measures of treatment adherence but
also on baseline and post-randomisation time-varying
covariates which impact on the decision to change
treatment. For example, IPCW methods require
adjustment for all known confounders which impact
both treatment changes and outcome.
Reporting and analysis of deviations from treatment
protocol
In order to ensure availability of necessary data and
protect against selective reporting, trialists need also
to consider at the design stage the statistical analysis
methods that will be employed to adjust for treatment
changes. First, it is necessary to consider the trial
aims and complications in interpreting ITT analysis
that may be introduced by any anticipated adherence
problems in order to determine whether analysis by
ITT is likely to be appropriate or sufficient [6].
Regardless of trial aims, however, reporting informa-
tion on the uptake and acceptance of treatment is
important for the interpretation of the success of the
trial treatments, even when analysis does not specific-
ally aim to adjust for nonadherence to treatment
protocol [4].
Reporting of compliance data
Even when clinicians are not interested in an explana-
tory analysis per se (but instead are interested in the
effectiveness of the policy of starting with a certain
treatment, for example), it is nevertheless important
for clinicians to be aware of what changes did occur;
otherwise, without an understanding of what the trial
treatment policy entailed or how it panned out, it is
not possible to fully interpret the effectiveness of the
trial treatment policy or to assess the similarity of the
trial setting to alternative clinical settings. Even when a
trial does not involve many treatment changes, this fact
should be communicated so that those interpreting the
results are aware that the ITT result is likely to closely
mirror the explanatory effect of treatment. Similarly, if a
trial is subject to such extreme non-compliance that the
results of any analysis are questionable, it is important that
the extent of non-compliance is clearly communicated in
order that readers appreciate that non-significant results
are related to adherence rather than the efficacy of treat-
ment per se. Thus, regardless of whether a trial is designed
and analysed to demonstrate effectiveness or efficacy of
treatment, or any measure in between, it is important to
provide a clear description of the degree and nature of
treatment changes.
Adherence information recorded in the trial should
be sufficiently detailed and accurate to allow reporting
of relevant features of nonadherence which are likely
to impact on the course of disease and associated
outcomes. Reporting of adherence must also relate to
the types of treatment changes expected or encour-
aged in the trial setting. For example, when treatment
switches or additions are likely, it may be relevant to
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record information not only on patients’ adherence
with their original randomised treatment but also
with any alternative treatments received, as well as
the timing of, and reasons for, such changes [14]. It
may also be of relevance to determine who or what
was responsible for the decision or request to change
treatment prescription (be that the patient, the treating
clinician or potentially the protocol itself) and whether
this decision was made in a blinded fashion [31].
Monitoring plan
To this end, it may be helpful to create a monitoring
plan which specifies how all relevant compliance data
will be collected, recorded and reported during the
course of the trial. Data should be collected in order to
ensure clinically relevant summaries of treatment adher-
ence can be created [32]. Reporting missing data is as
important as disclosure of treatment deviations, given
that the two are often related and interlinked [33]. In
particular, trial reports should distinguish withdrawal
due to LTFU from active decisions to exclude patients
from analysis (for example, due to withdrawal or
deviation from treatment protocol), which would require
appropriate causal methods to avoid subsequent selec-
tion bias [34].
Statistical analysis plan
Consideration of the statistical methods that will be
applied to adjust for nonadherence must also take place
during the design stage, not only to demonstrate trans-
parency with respect to the planned analyses but also to
ensure collection of all necessary information required
to facilitate the chosen methods of analysis. This is
especially important when considering how to adjust for
nonadherence, as adherence is rarely a simple dichotom-
ous measure and may fluctuate within individual over
the course of the trial, providing opportunities for ma-
nipulation of the particular definition of ‘nonadherence’
in a certain trial in order to produce the most favourable
results; for example, by excluding certain patients with
particularly good or poor prognoses [35, 36].
As such, in order to avoid accusations of bias, a spe-
cific analysis plan should accompany every trial protocol,
providing technical details of planned statistical analyses
[37]. The choice of statistical methods should be dis-
cussed and justified, given that each method has its own
different advantages and disadvantages and relies on differ-
ent assumptions, considering the use of sensitivity analyses
to assess departures from identifying assumptions.
Ideally, this plan should include definitions of ‘nonad-
herence’ and whether, and, if so, how, the efficacy analysis
will be adjusted for any nonadherence. These analyses
should be linked to the research questions of interest,
which then determine the corresponding forms of
nonadherence which need to be factored out in order to
investigate these questions. This may be a challenging
exercise, given the difficulty in predicting all forms of par-
ticipant or clinician nonadherence that will occur in a trial
and, therefore, in defining precisely how particular
patients’ data will be analysed (which may explain why,
despite the argument for upfront transparency, decisions
regarding adherence analyses are often made post hoc)
[35]. Indeed Cox [38] argues that although it is necessary
to provide a general plan of statistical analysis, it may be
unrealistic to require analysts to stick rigidly to specific
analysis plans, and that, following analyses carried out
according to the original plan, there may be justifiable
reasons for making amendments to specific analyses.
Thus, although it may be necessary to make changes
to the monitoring or statistical analysis plans during the
course of the trial, it is always necessary to disclose the
occurrence and reasons for such amendments in order
to ensure transparency and accountability.
Power and sample size
Analysts should consider the effect of nonadherence
or treatment changes on the power of trial analyses.
Non-compliance in a trial typically reduces the power
of ITT analyses because the treatment experiences of
randomised groups are more similar than intended.
Although it may seem natural to aim to recover this
lost power, it is often impossible to do so using the
methods discussed above without making additional
unverifiable assumptions regarding the comparability
of those who do, and do not, comply, such as those
underlying PP and AT analyses [5].
For this reason, potential loss of power caused by
non-compliance should be considered when planning
the sample size of a trial which aims to demonstrate
treatment efficacy. Given that it will rarely be possible
to regain the associated lost power, the initial sample
size should incorporate an inflation factor based on
realistic projections of relevant forms of nonadher-
ence or LFTU [39]. If the likely degree of nonadher-
ence is unknown, an adaptive design might be
employed, whereby an interim pilot assessment is
planned to check the rate of nonadherence midtrial,
with the option of increasing the target sample size
accordingly [40]. If causal analysis is a secondary
objective only, it may be useful to demonstrate the
impact of nonadherence on study power for illustra-
tive purposes only.
Snapinn et al. [31] demonstrate how informative non-
compliance impacts on sample size and power, discussing
different methods to allow for likely non-compliance rates
when planning trial sample sizes. The majority of the sam-
ple size methods available assume only treatment switches
to the alternative treatment and all assume that such
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discontinuation is independent of outcome (i.e. unin-
formative). They argue that this (latter) assumption can
lead to greatly underestimated sample sizes, because it is
not the rate of non-compliance per se, but rather the pro-
portion of endpoints occurring in non-compliant patients,
that impacts on power; they go on to demonstrate an al-
ternative method of determining sample size which allows
for informative dropout [31].
Discussion
The case studies presented in this paper demonstrate
how deviation from randomised treatment may be mani-
fested, in a variety of trial settings, and the subsequent
impact on interpretation of analyses. These trials are not
unique; the results of a recent review of reporting and
analysis of nonadherence in published trials demonstrate
clearly that deviation from randomised treatment is a
common problem affecting virtually all trials, but that
appropriate causal methodology to allow for these devia-
tions is rarely applied [4]. There is, therefore, a pressing
need to explore and address the barriers that prevent
trial statisticians from applying these more appropriate
causal methods to estimate efficacy of treatment when
faced with treatment deviations.
The culture of acceptance of ITT as the standard
method of analysis, along with a reluctance on the part of
trialists to consider alternative methods of analysis out of
fear of potentially introducing selection bias, has meant
that trials have typically been carried out with a strong
focus on pragmatic aims, thus deterring statisticians from
investigating or promoting alternatives methods of causal
analysis. However, there has recently been an increased
awareness (for example, on the part of regulatory or fund-
ing bodies) of alternative causal methods which can
appropriately address these potential biases [41], and a
number of submissions made to NICE [42–46] and the
Scottish Medical Consortium [47] have included adjust-
ment for treatment switches.
When such methods are introduced, their sheer com-
plexity, along with a lack of awareness or experience in
applying such methods in practice to what may be a com-
plex compliance trial scenario, may hinder their use. In
order to implement such methods, it is necessary to rec-
ognise how the treatment deviations in a given trial relate
to the research question of interest and impact on the
conclusions drawn from ITT analysis.
As such, this paper has presented a framework for tri-
alists to follow when considering adjusting for treatment
changes in trials, providing examples of when it may be
appropriate to consider estimation methods beyond ITT
and practical recommendations to ensure such analyses
are possible and legitimate. In order that suitable
methods of causal analysis can be implemented in prac-
tice, it is necessary for researchers to consider certain
issues at the design stage of the trial. Appropriate
planning is required to ensure the necessary data are
collected, not only regarding treatment adherence and
outcome, but also on all potential confounding factors
that may need to be accounted for. Furthermore, a
statistical analysis plan should be developed a priori to
ensure that trialists are not accused of altering analysis
techniques once outcome data have been collected and
observed in order to obtain optimal results.
In a complementary paper [11], we demonstrate how
to convert a relatively complex trial compliance scenario
into answerable research questions and estimable causal
effects. The paper describes the practical application of
two causal methods for a complicated time-to-event
outcome in the analysis of the SANAD trial, thereby
avoiding potential biases associated with commonly used
simple methods such as PP or AT analyses.
Summary of recommendations to trialists: considerations at trial design stage
1. Identify the extent and nature of deviations from randomised
treatment that are likely to occur during the course of the trial
2. Specify a priori definition of nonadherence and causal research
question of interest, identifying which treatment deviations can be
ignored and which should be factored out of analysis
3. Consider whether the expected extent and nature of treatment
deviations warrant implementing a particular trial design (such as
encouragement design or
SMART)
4. Determine necessary data that need to be collected to allow causal
analysis to be performed. Data should be collected in order to ensure
clinically relevant summaries of compliance can be created, including
the reasons for missing data. Collect data on baseline and
time-varying confounders (related to occurrence of treatment
changes and outcome), including determinants of treatment change.
Consider methods to maximise reliability of data (allowing for the
potential for distortion or inaccurate recall by patient, or
measurement error)
5. Trial reports should clearly communicate the degree and nature of
treatment changes, regardless of analysis aims. Create a monitoring
plan which specifies how all relevant compliance data will be
collected, recorded and reported during the course of the trial.
Include in the statistical analysis plan details of proposed statistical
analysis methods that will be suitable/possible with the available data
to answer the causal research question of interest. However, bear in
mind that the analysis plan may need to be amended, subject to
complications arising in analysis, in which case causal analyses should
be interpreted as exploratory analyses
6. If causal analysis is of primary interest, allow for potential loss of
power in sample size calculation, inflating necessary numbers
required by a projected percentage of missing outcome data. Use an
adaptive design if the likely degree of nonadherence is unknown,
with the option to increase target sample size midtrial depending on
the rate of nonadherence observed in the interim pilot
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